SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-002896
Filing Date
2024-01-18
Accepted
2024-01-18 16:00:42
Documents
16
Period of Report
2024-01-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 71521
2 ex3-1.htm EX-3.1 1050066
3 ex10-1.htm EX-10.1 27092
4 ex3-1_001.jpg GRAPHIC 2329
  Complete submission text file 0001493152-24-002896.txt   1483563

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE tenku-20240117.xsd EX-101.SCH 4090
6 XBRL DEFINITION FILE tenku-20240117_def.xml EX-101.DEF 27176
7 XBRL LABEL FILE tenku-20240117_lab.xml EX-101.LAB 37633
8 XBRL PRESENTATION FILE tenku-20240117_pre.xml EX-101.PRE 25796
10 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6599
Mailing Address 420 LEXINGTON AVE, SUITE 2446 NEW YORK NY 10017
Business Address 420 LEXINGTON AVE, SUITE 2446 NEW YORK NY 10017 (347) 627-0058
TenX Keane Acquisition (Filer) CIK: 0001851484 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41534 | Film No.: 24541753
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)